Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 6665
Affinity DataIC50: 0.00450nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00680nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00850nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0190nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0350nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0440nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0450nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0520nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.120nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.150nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.150nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.170nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.180nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.180nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.220nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.270nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.280nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.320nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.360nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.380nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.390nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.390nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.460nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.480nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.570nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.600nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.640nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.650nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.690nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.780nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.820nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.830nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.870nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 0.890nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 1.08nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 2.5nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Mitsubishi Tanabe Pharma
US Patent
Mitsubishi Tanabe Pharma
US Patent
Affinity DataIC50: 2.5nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
